Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trial results prompt scientists to call for greater use of stenting in left main artery

This article was originally published in Clinica

Executive Summary

Using stents to treat patients with left main coronary artery disease is safe and effective in the long term, a study has found. The SYNTAX-LE MANS substudy also concluded that drug-eluting stents (DESs) were a better choice than bare-metal stents (BMSs). The LE MANS registry enrolled 252 patients with unprotected left main coronary artery disease (ULMCA). In total, BMSs were used in 158 patients and DESs in 94 (37.3%). Within the DES group, paclitaxel-eluting stents were used in 60 (63.8%) patients, whereas limus analogue-eluting stents were used in 34 (36.2%) patients.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel